MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
07 Apr 2020
487
MedComm | Plasma therapy cured a COVID‐19 patient with long duration of viral shedding for 49 days
Scimea

COVID-19 has spread worldwide since it began in late 2019, becoming a threat to global health. Recently, Li Tan et al reported a special case of a family cluster with a mild type of COVID‐19, in which treatment with plasma from recovered COVID‐19 patients efficiently cleared out the virus infection.





image.png




Coronavirus disease‐19 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become a threat to global health. The clinical spectrum in COVID‐19 patients presents diversety. Viral shedding is a critical indicator for prognosis, and prolonged viral shedding always predicts a poor outcome. In this report, however, we describe a special case of a family cluster with a mild type of COVID‐19. In one family member, the duration from illness onset has persisted for over 49 days till now, which is the longest duration of viral shedding in symptomatic patients as far as we know. Nevertheless, this case shows a mild infectivity and a better status comparing with most cases. Fortunately, treatment with plasma from recovered COVID‐19 patients efficiently cleared out the virus infection. This report describes the detailed epidemiologic and clinical information of this special patient and his close contacts, which might provide rationale for reasonable treatment and public health management.

 



图片.png 

Fig. 1 Dynamic assessment of symptoms, body temperatures and viral infection status of Case 1 (A) and Case 2 (B) from 25 January to 19 March 2020.

 

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.2

 

 

                                                                                                        

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.


 


MedComm | Radiomics‐based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS‐CoV‐2) and influenza A infected pneumonia
Opening of the 15th West China Hospital International Orthopaedic Forum & the 23rd Orthopaedic Conference of Sichuan Medical Association and the Academic Conference of the Osteopathic Committee of SCIMEA
SCIMEA Medical Imaging Committee Holds a Preparatory Meeting
Member Unit News | Easton Biopharmaceuticals' Listing Application Accepted
Molecular Biomedicine | A promising vaccine candidate against COVID-19
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1